Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan.
Division of Trauma and Emergency Surgery, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
JAMA Netw Open. 2019 Feb 1;2(2):e187861. doi: 10.1001/jamanetworkopen.2018.7861.
Thoracic endovascular aortic repair (TEVAR) has been adopted rapidly for treating traumatic thoracic aortic injury (TAI). The long-term durability and efficacy remain unknown.
To determine the long-term outcomes of thoracic endovascular aortic repair and those of open repair (OR) for traumatic TAI.
DESIGN, SETTING, PARTICIPANTS: This nationwide cohort study used Taiwan's National Health Insurance Database to evaluate patients with traumatic TAI between January 1, 2004, and December 31, 2013. This single-payer National Health Insurance program covered more than 99.9% of the Taiwanese population. Those who received OR or TEVAR for TAI by propensity score matching were included. Data analysis was conducted in October 2017.
Thoracic endovascular aortic repair vs open repair.
In-hospital outcomes, all-cause mortality, aorta reintervention, and stroke during follow-up.
Of the 287 patients (mean [SD] age, 41.66 [17.98] years; 80.5% male) who received OR or TEVAR for TAI, propensity score matching yielded 100 patients each in the OR and TEVAR groups. After propensity score matching, in-hospital mortality risk was significantly lower in the TEVAR group (9 [9.0%]) than in the OR group (27 [27.0%]; TEVAR vs open repair: odds ratio, 0.27; 95% CI, 0.12-0.60). With a mean (SD) follow-up of 2.80 (2.63) years, the proportion of survivors was 71.9% at 1 year, 70.8% at 2 years, 68.2% at 3 years, and 65.1% at 5 years in the OR group vs 88.9% at 1 year, 88.9% at 2 years, 88.9% at 3 years, and 88.9% at 5 years in the TEVAR group (log-rank test, P < .001). The TEVAR group had only 2 events (2%) of late reintervention and 1 event (1%) of late cerebrovascular accident. The proportion of freedom from reintervention was 100% at 1 year, 100% at 2 years, 100% at 3 years, and 100% at 5 years in the OR group vs 97.4% at 1 year, 97.4% at 2 years, 97.4% at 3 years, and 97.4% at 5 years in the TEVAR group (log-rank test, P = .18).
Compared with OR, TEVAR was associated with better long-term outcomes, mainly owing to lower mortality during the perioperative period. In addition, TEVAR was associated with a similar rate of survival and reintervention after hospital discharge.
胸主动脉腔内修复术(TEVAR)已被迅速用于治疗创伤性胸主动脉损伤(TAI)。其长期耐久性和疗效仍不清楚。
确定胸主动脉腔内修复术和开放性修复术(OR)治疗创伤性 TAI 的长期结果。
设计、环境、参与者:本全国性队列研究使用台湾全民健康保险数据库评估 2004 年 1 月 1 日至 2013 年 12 月 31 日期间患有创伤性 TAI 的患者。该单一支付者全民健康保险计划覆盖了超过 99.9%的台湾人口。符合条件的患者接受了 TAI 的 OR 或 TEVAR。数据分析于 2017 年 10 月进行。
胸主动脉腔内修复术与开放性修复术。
住院期间结局、全因死亡率、主动脉再干预以及随访期间的中风。
在 287 名(平均[标准差]年龄 41.66[17.98]岁;80.5%为男性)接受 OR 或 TEVAR 治疗 TAI 的患者中,通过倾向评分匹配后,每组各有 100 名患者纳入 OR 和 TEVAR 组。在倾向评分匹配后,TEVAR 组(9[9.0%])的住院死亡率明显低于 OR 组(27[27.0%];TEVAR 与开放修复术:比值比,0.27;95%CI,0.12-0.60)。在平均(标准差)2.80(2.63)年的随访中,OR 组 1 年时的生存率为 71.9%,2 年时为 70.8%,3 年时为 68.2%,5 年时为 65.1%,而 TEVAR 组 1 年时为 88.9%,2 年时为 88.9%,3 年时为 88.9%,5 年时为 88.9%(对数秩检验,P < .001)。TEVAR 组仅发生 2 例(2%)晚期再干预事件和 1 例(1%)晚期脑血管意外事件。OR 组 1 年、2 年、3 年和 5 年的无再干预率分别为 100%、100%、100%和 100%,TEVAR 组分别为 97.4%、97.4%、97.4%和 97.4%(对数秩检验,P = .18)。
与 OR 相比,TEVAR 与更好的长期结局相关,主要归因于围手术期死亡率较低。此外,TEVAR 与出院后的生存和再干预率相似。